FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308395738> ?p ?o ?g. }

• W4308395738 abstract "<h3>Background</h3> Despite major improvement of overall survival of HER2+ MBC with effective HER2 targeted therapies, many patients experience significant toxicities and develop progressive disease during treatment. Therefore, new and more effective therapeutic options are needed. This novel approach will evaluate whether the combination of three immunotherapies in addition to trastuzumab: dendritic cell (DC) vaccination, anti-SEMA4D blocking antibody(pepinemab) and CD4+ T cell adoptive transfer can lead to improved outcomes for patients with MBC refractory to HER2-targeted agents. BC have been considered as immunologically cold which is attributed to immune evasion and suppression of host effector immune cells homing into tumor bed. Progressive loss of Th1 immunity against HER2 oncodriver correlates with poor prognosis. HER2 peptide pulsed type I dendritic cells (HER2-DC1) restored anti-HER2 CD4+ Th1 immune response and improved pathologic complete response (pCR) in HER2+ BC.¹ Antibodies to SEMA4D have been shown to modulate the TME by increasing effector cell infiltration and reducing immunosuppression.¹ In preclinical studies, treatment with anti-SEMA4D and HER2-DC1 in mice bearing established HER2+ tumors improved DC homing, expansion of CD4+ T cells, and complete tumor regression, compared to treatment with anti-SEMA4D or HER2-DC1 alone. Further, subsequent expansion and adoptive transfer of CD4+ T cells induced synergistic anti-tumor activity by activating CD8+ T mediated cytotoxicity. Pepinemab was well-tolerated^2,3 and showed signs of anti-tumor activity in in immunotherapy-resistant, PD-L1 negative/low non-small cell lung cancer patients when combined with checkpoint inhibitor (avelumab).³ <h3>Methods</h3> This open label Phase 1 study is enrolling up to 28 patients with HER2+ MBC. Patients will be treated with 6 weekly injections of dendritic cell (DC1) vaccines in combination with trastuzumab and pepinemab. We hypothesize these therapies may elicit CD4+ HER2-specific T cell responses. HER2-specific T cells will be expanded ex vivo and subsequently infused to patients following lymphodepletion with cyclophosphamide. Trastuzumab and pepinemab will be given as maintenance in addition to booster DC1 vaccines. Patients (ECOG 0,1) must have had disease progression while on trastuzumab for the treatment of HER2+ MBC and received no more than 3 lines of therapy in the setting of metastatic disease. Dose escalation will consist of 3-6 patients each with increasing amounts of transferred CD4+ T cells, followed by dose expansion of 10 patients at the MTD. The primary objective is safety and tolerability; secondary objectives will include evaluation of T cell immunity and immune subsets, efficacy, PK/PD/ADA of pepinemab, and biomarker assessments. <h3>Trial Registration</h3> NCT05378464 <h3>References</h3> Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, Roses RE, Czerniecki BJ. Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial. <i>Clin Cancer Res.</i> 2017;<b>23</b>(12):2961–2971. Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, Blaydorn L, Tolcher AW, Zauderer M, Ramanathan RK. Safety, Pharmacokinetics, and Pharmacodynamics of a Humanized Anti-Semaphorin 4D Antibody, in a First-In-Human Study of Patients with Advanced Solid Tumors. <i>Clin Cancer Res</i>. 2016;<b>22</b>(4):827–36. Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Mishra V, Schröder A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. <i>Clin Cancer Res</i>. 2021;<b>27</b>(13):3630–3640. <h3>Ethics Approval</h3> This study was approved by Advarra; approval number IRB# 00000971" @default.
• W4308395738 created "2022-11-11" @default.
• W4308395738 creator A5014209331 @default.
• W4308395738 creator A5014744153 @default.
• W4308395738 creator A5021394406 @default.
• W4308395738 creator A5021935697 @default.
• W4308395738 creator A5021992802 @default.
• W4308395738 creator A5022624265 @default.
• W4308395738 creator A5026765782 @default.
• W4308395738 creator A5031071900 @default.
• W4308395738 creator A5036474702 @default.
• W4308395738 creator A5046645773 @default.
• W4308395738 creator A5051916408 @default.
• W4308395738 creator A5052301018 @default.
• W4308395738 creator A5055261814 @default.
• W4308395738 creator A5059240684 @default.
• W4308395738 creator A5069437923 @default.
• W4308395738 creator A5089699061 @default.
• W4308395738 creator A5090789911 @default.
• W4308395738 date "2022-11-01" @default.
• W4308395738 modified "2023-09-27" @default.
• W4308395738 title "645 Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC)" @default.
• W4308395738 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0645" @default.
• W4308395738 hasPublicationYear "2022" @default.
• W4308395738 type Work @default.
• W4308395738 citedByCount "0" @default.
• W4308395738 crossrefType "proceedings-article" @default.
• W4308395738 hasAuthorship W4308395738A5014209331 @default.
• W4308395738 hasAuthorship W4308395738A5014744153 @default.
• W4308395738 hasAuthorship W4308395738A5021394406 @default.
• W4308395738 hasAuthorship W4308395738A5021935697 @default.
• W4308395738 hasAuthorship W4308395738A5021992802 @default.
• W4308395738 hasAuthorship W4308395738A5022624265 @default.
• W4308395738 hasAuthorship W4308395738A5026765782 @default.
• W4308395738 hasAuthorship W4308395738A5031071900 @default.
• W4308395738 hasAuthorship W4308395738A5036474702 @default.
• W4308395738 hasAuthorship W4308395738A5046645773 @default.
• W4308395738 hasAuthorship W4308395738A5051916408 @default.
• W4308395738 hasAuthorship W4308395738A5052301018 @default.
• W4308395738 hasAuthorship W4308395738A5055261814 @default.
• W4308395738 hasAuthorship W4308395738A5059240684 @default.
• W4308395738 hasAuthorship W4308395738A5069437923 @default.
• W4308395738 hasAuthorship W4308395738A5089699061 @default.
• W4308395738 hasAuthorship W4308395738A5090789911 @default.
• W4308395738 hasBestOaLocation W43083957381 @default.
• W4308395738 hasConcept C121608353 @default.
• W4308395738 hasConcept C126322002 @default.
• W4308395738 hasConcept C167672396 @default.
• W4308395738 hasConcept C203014093 @default.
• W4308395738 hasConcept C2775930923 @default.
• W4308395738 hasConcept C2776090121 @default.
• W4308395738 hasConcept C2777701055 @default.
• W4308395738 hasConcept C2778170410 @default.
• W4308395738 hasConcept C2779786085 @default.
• W4308395738 hasConcept C502942594 @default.
• W4308395738 hasConcept C530470458 @default.
• W4308395738 hasConcept C71924100 @default.
• W4308395738 hasConcept C8891405 @default.
• W4308395738 hasConcept C90375314 @default.
• W4308395738 hasConceptScore W4308395738C121608353 @default.
• W4308395738 hasConceptScore W4308395738C126322002 @default.
• W4308395738 hasConceptScore W4308395738C167672396 @default.
• W4308395738 hasConceptScore W4308395738C203014093 @default.
• W4308395738 hasConceptScore W4308395738C2775930923 @default.
• W4308395738 hasConceptScore W4308395738C2776090121 @default.
• W4308395738 hasConceptScore W4308395738C2777701055 @default.
• W4308395738 hasConceptScore W4308395738C2778170410 @default.
• W4308395738 hasConceptScore W4308395738C2779786085 @default.
• W4308395738 hasConceptScore W4308395738C502942594 @default.
• W4308395738 hasConceptScore W4308395738C530470458 @default.
• W4308395738 hasConceptScore W4308395738C71924100 @default.
• W4308395738 hasConceptScore W4308395738C8891405 @default.
• W4308395738 hasConceptScore W4308395738C90375314 @default.
• W4308395738 hasLocation W43083957381 @default.
• W4308395738 hasOpenAccess W4308395738 @default.
• W4308395738 hasPrimaryLocation W43083957381 @default.
• W4308395738 hasRelatedWork W1488028176 @default.
• W4308395738 hasRelatedWork W2000342552 @default.
• W4308395738 hasRelatedWork W2017350327 @default.
• W4308395738 hasRelatedWork W2032597637 @default.
• W4308395738 hasRelatedWork W2055715607 @default.
• W4308395738 hasRelatedWork W2367344610 @default.
• W4308395738 hasRelatedWork W2387430262 @default.
• W4308395738 hasRelatedWork W2844031422 @default.
• W4308395738 hasRelatedWork W2969859807 @default.
• W4308395738 hasRelatedWork W3112956305 @default.
• W4308395738 isParatext "false" @default.
• W4308395738 isRetracted "false" @default.
• W4308395738 workType "article" @default.